Details:
The licensing deal with TOI includes a significant upfront payment, sizeable clinical and regulatory milestones and double-digit royalties. As part of the Licensing Agreement, TOI will also manage and finance the Phase III pivotal trials for IBE-814 IVT.
Lead Product(s): Dexamethasone
Therapeutic Area: Ophthalmology Product Name: IBE-814 IVT
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Laboratoires Thea
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement December 15, 2020
Details:
Along with a Series A The licensing deal with TOI includes a significant upfront payment, sizeable clinical and regulatory milestones and double-digit royalties. As part of the Licensing Agreement, TOI will also manage and finance the Phase III pivotal trials for IBE-814 IVT.
Lead Product(s): Dexamethasone
Therapeutic Area: Ophthalmology Product Name: IBE-814 IVT
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Laboratoires Thea
Deal Size: $22.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing December 15, 2020